Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr;42(4):292-296.
doi: 10.1097/DAD.0000000000001527.

Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report

Shamika Robinson  1 , Jasmine Saleh  1 , Jonathan Curry  2 , Kumaran Mudaliar  1
Affiliations
Case Reports

Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report

Shamika Robinson et al. Am J Dermatopathol. 2020 Apr.

Abstract

We present a rare case of a pembrolizumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). A 55-year-old woman with a history of metastatic cervical squamous cell carcinoma presented with a widespread mucocutaneous rash. Seventeen days after receiving her first cycle of pembrolizumab, she presented with fever, difficulty breathing, watery eyes, and painful oral ulcers. Physical examination revealed widespread erythematous papules and papulovesicles involving the trunk, upper extremity, and lower extremity and hemorrhagic plaques on the lower lip and buccal mucosa. Biopsy confirmed a diagnosis of SJS/TEN. This case highlights the importance of awareness of SJS/TEN as a possible adverse reaction for patients receiving pembrolizumab, a medication increasingly being used to treat metastatic or unresectable malignancies.

PubMed Disclaimer

References

    1. Abe R. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatol. 2015;42:42–48.
    1. Miliszewski MA, Kirchhof MG, Sikora S, et al. Stevens-johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129:1221–1225.
    1. Keytruda (Pembrolizumab). Highlights of Prescribing Information. 2018. Available at: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed March 17, 2019.
    1. Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22:4023–4029.
    1. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44:381–384.

Publication types

MeSH terms

Substances